Company Analysis
Sign in

Halozyme Therapeutics, Inc. (HALO)

Nasdaq: HALO · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2001
Full chart Alerts Compare
Grade6.8
◀ Past 7.9● Present 7.3▶ Future 5.2
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

202 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Halozyme Therapeutics, Inc.’s names, not what it holds today.

Patents granted
202
196 utility, 4 design, 2 reissue, 1976 to Dec 31, 2025
Granted in 2025
11
Against 22 in 2024 and 11 in 2023
Applications published
217
27 of them in 2025
Names they are printed under
6
a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals33
Medical technology26
Control1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
Antares Pharma, Inc. a subsidiary
US, as the owner printed on each patent
110 granted
111 published
Halozyme, Inc. a subsidiary
US, as the owner printed on each patent
76 granted
28 published
Halozyme, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
49 published
Antares Pharma IPL AG a subsidiary
CH, as the owner printed on each patent
16 granted
10 published
Antares Pharma, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
18 published
Antares Pharma IPL AG a subsidiary
named as the applicant on its applications, in CH
0 granted
1 published
Names not counted (1)
HALOZYME THERAPEUTICS, INC.
No country is printed for it. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 2025D1,107,901Injection deviceHalozyme, Inc.
Dec 9, 2025D1,105,416Injection deviceHalozyme, Inc.
Oct 28, 202512,453,819InjectorMedical technologyAntares Pharma, Inc.
Sep 9, 2025D1,092,725Injection deviceHalozyme, Inc.
Sep 9, 202512,409,272Prefilled syringe with breakaway force featureMedical technologyAntares Pharma, Inc.
Jul 29, 202512,371,685PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereofPharmaceuticalsHalozyme, Inc.
Jul 15, 202512,357,642Hazardous agent injection systemMedical technologyAntares Pharma, Inc.
Jun 3, 202512,318,581Needle assisted injection device having reduced trigger forcePharmaceuticalsAntares Pharma, Inc.
Apr 1, 202512,264,345PH20 polypeptide variants, formulations and uses thereofPharmaceuticalsHalozyme, Inc.
Feb 11, 202512,220,560Needle assisted injection device having reduced trigger forceMedical technologyAntares Pharma, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 20, 20252025/0352736Injector Having a Guard AssemblyMedical technologyHalozyme, Inc.
Nov 20, 20252025/0352729PREFILLED SYRINGE WITH BREAKAWAY FORCE FEATUREMedical technologyAntares Pharma, Inc.
Nov 13, 20252025/0345521InjectorMedical technologyAntares Pharma, Inc.
Oct 9, 20252025/0312424Hyaluronidase Enzyme Formulations for High Volume AdministrationPharmaceuticalsHalozyme, Inc.
Sep 25, 20252025/0295857Auto-Insert InjectorMedical technologyAntares Pharma, Inc.
Sep 25, 20252025/0295671Hazardous Agent Injection SystemMedical technologyAntares Pharma, Inc.
Jul 10, 20252025/0222204InjectorMedical technologyHalozyme, Inc.
Jul 10, 20252025/0222078MODIFIED HYALURONIDASES AND USES IN TREATING HYALURONAN-ASSOCIATED DISEASES AND CONDITIONSPharmaceuticalsHalozyme, Inc.
Jun 26, 20252025/0205334Antibody Compositions and Methods of Use ThereofPharmaceuticalsHalozyme, Inc.
Jun 19, 20252025/0197836PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFPharmaceuticalsHalozyme, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 31 · Medical technology 14.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton HALO · research, not advice